Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

Ashraf Alzaabi; John P. Bell; Felicia Montero-Arias; David B. Price; David J. Jackson; Hao-Chien Wang; Nigel Budgen; Hisham Farouk; Ekaterina Maslova

doi:10.1007/s12325-023-02663-2

Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

Ashraf Alzaabi, John P. Bell, Felicia Montero-Arias, David B. Price, David J. Jackson, Hao-Chien Wang, Nigel Budgen, Hisham Farouk, Ekaterina Maslova

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.

Original language	English
Pages (from-to)	4836-4856
Number of pages	21
Journal	Advances in Therapy
Volume	40
Issue number	11
Early online date	9 Sept 2023
DOIs	https://doi.org/10.1007/s12325-023-02663-2
Publication status	Published - Nov 2023

Bibliographical note

Acknowledgements
Medical Writing, Editorial, and Other Assistance
Medical writing and editorial support were provided by Tejaswini Subbannayya, PhD, of Cactus Life Sciences (part of Cactus Communications, Mumbai, India), in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca.

Funding
AstraZeneca funded the study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review the manuscript before submission. AstraZeneca also funded medical writing support and the development of the graphical abstract. AstraZeneca funded the journal’s Rapid Service and Open Access fees.

Data Availability Statement

Data underlying the SABINA III findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Data for clinical research studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for clinical research studies not listed on Vivli could be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. AstraZeneca Vivli member page is also available outlining further details: https://vivli.org/ourmember/astrazeneca/.

Keywords

Asthma
Asthma control
carbon footprint
Environmental monitoring
Greenhouse gas emissions
Inhalers
Inhaler therapies
SABA
Short-acting β2-agonist

Access to Document

10.1007/s12325-023-02663-2Licence: CC BY-NC

Alzaabi_etal_AT_Greenhouse_Gas_Emissions_VoR
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Final published version, 1.25 MBLicence: CC BY-NC

Cite this

@article{6b352fac3bed44e8add6ea84a81c265c,

title = "Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study",

abstract = "Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.",

keywords = "Asthma, Asthma control, carbon footprint, Environmental monitoring, Greenhouse gas emissions, Inhalers, Inhaler therapies, SABA, Short-acting β2-agonist",

author = "Ashraf Alzaabi and Bell, {John P.} and Felicia Montero-Arias and Price, {David B.} and Jackson, {David J.} and Hao-Chien Wang and Nigel Budgen and Hisham Farouk and Ekaterina Maslova",

note = "Acknowledgements Medical Writing, Editorial, and Other Assistance Medical writing and editorial support were provided by Tejaswini Subbannayya, PhD, of Cactus Life Sciences (part of Cactus Communications, Mumbai, India), in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Funding AstraZeneca funded the study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review the manuscript before submission. AstraZeneca also funded medical writing support and the development of the graphical abstract. AstraZeneca funded the journal{\textquoteright}s Rapid Service and Open Access fees.",

year = "2023",

month = nov,

doi = "10.1007/s12325-023-02663-2",

language = "English",

volume = "40",

pages = "4836--4856",

journal = "Advances in Therapy",

issn = "1865-8652",

publisher = "Springer ",

number = "11",

}

TY - JOUR

T1 - Greenhouse Gas Emissions from Respiratory Treatments

T2 - Results from the SABA CARBON International Study

AU - Alzaabi, Ashraf

AU - Bell, John P.

AU - Montero-Arias, Felicia

AU - Price, David B.

AU - Jackson, David J.

AU - Wang, Hao-Chien

AU - Budgen, Nigel

AU - Farouk, Hisham

AU - Maslova, Ekaterina

N1 - Acknowledgements Medical Writing, Editorial, and Other Assistance Medical writing and editorial support were provided by Tejaswini Subbannayya, PhD, of Cactus Life Sciences (part of Cactus Communications, Mumbai, India), in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Funding AstraZeneca funded the study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review the manuscript before submission. AstraZeneca also funded medical writing support and the development of the graphical abstract. AstraZeneca funded the journal’s Rapid Service and Open Access fees.

PY - 2023/11

Y1 - 2023/11

N2 - Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.

AB - Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.

KW - Asthma

KW - Asthma control

KW - carbon footprint

KW - Environmental monitoring

KW - Greenhouse gas emissions

KW - Inhalers

KW - Inhaler therapies

KW - SABA

KW - Short-acting β2-agonist

U2 - 10.1007/s12325-023-02663-2

DO - 10.1007/s12325-023-02663-2

M3 - Article

C2 - 37684493

SN - 1865-8652

VL - 40

SP - 4836

EP - 4856

JO - Advances in Therapy

JF - Advances in Therapy

IS - 11

ER -

Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

Abstract

Bibliographical note

Data Availability Statement

Keywords

Access to Document

Fingerprint

Cite this